British Technology Group (now BTG plc), known for producing drugs to treat overdoses and rattlesnake bites, was formed in 1981 as a result of the merger of the National Research & Development Council and the National Enterprise Board of the UK government. A range of medical innovations along the way and several acquisitions later, BTG today is an international healthcare company focused on interventional medicine.
In late November 2018, Boston Scientific Corporation (BSC) announced that it would be acquiring BTG plc for USD 4.2 billion. Boston Scientific manufactures medical devices with interventional medical specialities. The acquisition will help Boston Scientific enhance its technology coverage and capabilities in interventional medicine.
In this report, we take a closer look at the patent portfolios of BTG and BSC using the taxonomy analytics generated by Relecura.
The report includes a detailed comparison of the portfolios of BTG and BSC. The comparison determines the value that acquiring BTG’s portfolio brings to BSC’s current patent assets. It shows how well the patent portfolios of both the companies complement each other and takes a closer look at the patent quality of the assets held by each.
The report considers the different M&A IP scenarios that might have played out. These include attempting to determine which other companies could have been potential acquirers for BTG. On the flip side, it analyzes other options that Boston Scientific might have considered as potential acquisitions, that were comparable to BTG from an IP standpoint.
Read our report to get all the analysis details and insights.
Relecura’s forte is its flexibility and adaptability to address specific problems and close-fitting solutions. The basic problem is that innovators are often not able to identify the industrial and commercial significance of their innovation as due diligence takes long days of analyses, necessitating a deviation from their regular and familiar activities. And it is a tedious iteration process. The latest custom AI capabilities help you assess the commercial value of innovation and technical due diligence can be automated to yield meaningful and immediate results. The repetitive tasks could be automated, and your time and energy could be devoted to strategic missions.
Management of large Innovation data is costly and labor intensive. Relecura offers AI-powered classification tools for categorizing and organizing data automatically and instantly. Automated Categorization against suitably chosen training documents keeps your innovation portfolio updated and lucidly classified, amenable to instant analyses.
Relecura offers fully automated custom AI solutions to track and explore developments in different technology areas. You can stay updated on the latest developments in different companies and technologies of your interest, which facilitates intelligent decision-making.
Competitive intelligence is a prerequisite for strategic decision making. Relecura provides tools to track the innovation and publication dynamics of your competitors, based on which you can prioritize your innovation initiatives and thus hone up your competitive edge.
Relecura uses white space analysis within its product platform known as the TechTracker, an AI-powered tool that provides insights on various technological trends and offers a peep into your competitor’s patent arsenal. Additionally, it helps you keep track of emerging organizations and technologies to help you manage your budgets and investments, optimally.
Make faster, better technology decisions with Relecura
Our professional services offer training and support to minimise time-to-value on the Relecura platform and make more timely, confident IP decisions